Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

Episode 380

0:00-32:25

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it. The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in treating depression. View full story: https://www.biocentury.com/article/660376 #BiotechMA #FDA #Psychedelics #Depression #OncolyticVirus 00:00 - Introduction 00:51 - AZ-BMS Rumors 08:07 - Replimune 20:46 - Psychedelics To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Publisher

BioCentury This Week

Published

August 4, 2026

Duration

32 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

BioCentury

BT

BioCentury This Week

@biocenturythisweek

#bmsrumors #replimune #psychedelics #lifesciences

The Nile